Review



parp1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech parp1
    Parp1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 779 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parp1/product/Proteintech
    Average 96 stars, based on 779 article reviews
    parp1 - by Bioz Stars, 2026-02
    96/100 stars

    Images



    Similar Products

    copy number variation parp1 hs02649938 cn  (Thermo Fisher)
    94
    Thermo Fisher copy number variation parp1 hs02649938 cn
    Copy Number Variation Parp1 Hs02649938 Cn, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/copy number variation parp1 hs02649938 cn/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    copy number variation parp1 hs02649938 cn - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    protease inhibitor medchemexpress cat  (MedChemExpress)
    94
    MedChemExpress protease inhibitor medchemexpress cat
    Protease Inhibitor Medchemexpress Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protease inhibitor medchemexpress cat/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    protease inhibitor medchemexpress cat - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    cleaved parp1  (Bethyl)
    93
    Bethyl cleaved parp1
    Cleaved Parp1, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cleaved parp1/product/Bethyl
    Average 93 stars, based on 1 article reviews
    cleaved parp1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    parp1 protacs sk 575  (MedChemExpress)
    94
    MedChemExpress parp1 protacs sk 575
    A) Structure <t>of</t> <t>SK-575</t> PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of <t>PARP1</t> expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.
    Parp1 Protacs Sk 575, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parp1 protacs sk 575/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    parp1 protacs sk 575 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    parp1 colorimetric assay kit  (BPS Bioscience)
    94
    BPS Bioscience parp1 colorimetric assay kit
    A) Structure <t>of</t> <t>SK-575</t> PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of <t>PARP1</t> expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.
    Parp1 Colorimetric Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parp1 colorimetric assay kit/product/BPS Bioscience
    Average 94 stars, based on 1 article reviews
    parp1 colorimetric assay kit - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    parp1  (Proteintech)
    96
    Proteintech parp1
    A) Structure <t>of</t> <t>SK-575</t> PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of <t>PARP1</t> expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.
    Parp1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parp1/product/Proteintech
    Average 96 stars, based on 1 article reviews
    parp1 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    compounds against parp1  (BPS Bioscience)
    94
    BPS Bioscience compounds against parp1
    A) Structure <t>of</t> <t>SK-575</t> PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of <t>PARP1</t> expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.
    Compounds Against Parp1, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compounds against parp1/product/BPS Bioscience
    Average 94 stars, based on 1 article reviews
    compounds against parp1 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    total parp  (Proteintech)
    96
    Proteintech total parp
    A) Structure <t>of</t> <t>SK-575</t> PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of <t>PARP1</t> expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.
    Total Parp, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total parp/product/Proteintech
    Average 96 stars, based on 1 article reviews
    total parp - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    parp1 protein  (MedChemExpress)
    94
    MedChemExpress parp1 protein
    A) Structure <t>of</t> <t>SK-575</t> PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of <t>PARP1</t> expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.
    Parp1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/parp1 protein/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    parp1 protein - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Structure of SK-575 PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of PARP1 expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.

    Journal: bioRxiv

    Article Title: PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugs

    doi: 10.64898/2026.01.12.698947

    Figure Lengend Snippet: A) Structure of SK-575 PROTAC formed by the PARPi Olaparib linked to Thalidomide, a CRBN binder. B) Western blot analysis of PARP1 expression in isogenic CRBN WT and KO KBM7 cells treated with 100 nM SK-575 or Thalidomide for 48h. ACTB was used as loading control. C) Viability assay by MTT performed in CRBN WT or KO KBM7 cells pre-treated with 100 nM SK-575 for 24 h followed by a treatment with both SK-575 and the indicated doses of Olaparib or Talazoparib for another 24 h. Data are normalized to vehicle or SK-575 pre-treated cells and correspond to three biological replicates. IC50s were calculated with non-linear regression analysis and are shown in the figure (µM). Statistical significance was determined with Extra sum-of-squares F test. D) Analysis of percentage of viability as assessed by Annexin V/PI staining using flow cytometry analysis from three biological replicates. Statistical significance was determined with Ordinary one-way ANOVA and Tukey’s multiple comparisons test. E) Representative images of the Annexin V/PI staining. Percentage of cells for each population are shown. F) Western blot showing PARP1 degradation in human bone marrow mononuclear cells treated with 100 nM SK-575 for 48 h. G) Colony-forming cells (CFC) assay of human bone marrow mononuclear cells pre-treated with 100 nM SK-575 24 h before seeding them in MethoCult semi-solid methylcellulose-based media with the indicated doses of Talazoparib with or without 100 nM SK-575. Colonies were quantified after 14 days. Error bars indicate mean ± s.d. (n = 3). Statistical significance was determined with unpaired t-tests. In all the figures * = p < 0.05, and *** = p < 0.001.

    Article Snippet: Cells were treated with the following compounds at the indicated doses: BRD4 PROTAC A1874 (HY-114305, MedChemExpress) at 1 μM; PARP1 PROTACs SK-575 (HY-139156, MedChemExpress) at 100 nM and 180055 (HY-170620, MedChemExpress) at 1 μM; and PARP inhibitors Talazoparib (HY-16106, MedChemExpress) and Olaparib (HY-10162, MedChemExpress) at concentrations ranging from 48 μM to 0.02 μM in 3-fold dilutions.

    Techniques: Western Blot, Expressing, Control, Viability Assay, Staining, Flow Cytometry